Literature DB >> 33174187

Involvement of PTEN and FOXO3a Proteins in the Protective Activity of Protocatechuic Acid Against Cisplatin-Induced Ovarian Toxicity in Mice.

Bruna Bortoloni Gouveia1, Ricássio de Sousa Barberino1, Regina Lucia Dos Santos Silva1, Thae Lanne Barbosa Gama Lins1, Valéria da Silva Guimarães1, Alane Pains Oliveira do Monte1, Raimundo Campos Palheta2, Maria Helena Tavares de Matos3,4.   

Abstract

The present study evaluated the effects of protocatechuic acid (PCA) after cisplatin-induced ovarian toxicity in mice and if PTEN and FOXO3a proteins are involved in PCA action. The mice were divided into five experimental groups (five animals per group) and treated once a day for 3 days as follows: (1) the control group was pretreated with oral administration (o.p.) of saline solution, followed by an intraperitoneal (i.p.) injection of saline solution. The other groups were pretreated (o.p.) with (2) saline solution (cisplatin group), (3) N-acetylcysteine (150 mg/kg of body weight), or with (4) 20 or (5) 50 mg/kg body weight of PCA, followed by 5 mg/kg body weight (i.p.) of cisplatin. Next, the ovaries were destined to histological (morphology and activation), immunohistochemical (PCNA and cleaved caspase-3 expression), and fluorescence (reactive oxygen species [ROS], glutathione [GSH], and active mitochondria levels) analyses. Moreover, the immunoreactivity for p-PTEN and p-FOXO3a was evaluated to investigate a potential mechanism by which PCA could prevent the cisplatin-induced ovarian damage. Pretreatment with N-acetylcysteine or 20 mg/kg PCA before cisplatin preserved the percentage of normal follicles and cell proliferation as observed in the control, reduced apoptosis and ROS levels, and showed higher active mitochondria and GSH levels than the cisplatin treatment (P < 0.05). Moreover, pretreatment with 20 mg/kg PCA decreased cisplatin-induced p-PTEN and increased (P < 0.05) nuclear export of p-FOXO3a. In conclusion, PCA at 20 mg/kg reduced apoptosis, maintained cell proliferation and mitochondrial function, reduced ROS production, and increased GSH expression likely through the involvement of PTEN and FOXO3a proteins.

Entities:  

Keywords:  Fertility preservation; Ovary; Oxidative stress; Premature ovarian failure; Protein kinase

Year:  2020        PMID: 33174187     DOI: 10.1007/s43032-020-00305-4

Source DB:  PubMed          Journal:  Reprod Sci        ISSN: 1933-7191            Impact factor:   3.060


  24 in total

Review 1.  The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism.

Authors:  Jeffrey A Engelman; Ji Luo; Lewis C Cantley
Journal:  Nat Rev Genet       Date:  2006-08       Impact factor: 53.242

2.  Foxo3 is a PI3K-dependent molecular switch controlling the initiation of oocyte growth.

Authors:  George B John; Teresa D Gallardo; Lane J Shirley; Diego H Castrillon
Journal:  Dev Biol       Date:  2008-06-20       Impact factor: 3.582

3.  Pharmacotherapy to protect ovarian function and fertility during cancer treatment.

Authors:  Matteo Lambertini; Chiara Dellepiane; Giulia Viglietti; Lucia Del Mastro
Journal:  Expert Opin Pharmacother       Date:  2017-04-11       Impact factor: 3.889

4.  Conjugated linoleic acids attenuate FSH- and IGF1-stimulated cell proliferation; IGF1, GATA4, and aromatase expression; and estradiol-17β production in buffalo granulosa cells involving PPARγ, PTEN, and PI3K/Akt.

Authors:  Isha Sharma; Dheer Singh
Journal:  Reproduction       Date:  2012-06-25       Impact factor: 3.906

5.  Cisplatin- and cyclophosphamide-induced primordial follicle depletion is caused by direct damage to oocytes.

Authors:  Q N Nguyen; N Zerafa; S H Liew; J K Findlay; M Hickey; K J Hutt
Journal:  Mol Hum Reprod       Date:  2019-08-01       Impact factor: 4.025

Review 6.  How do chemotherapeutic agents damage the ovary?

Authors:  S Morgan; R A Anderson; C Gourley; W H Wallace; N Spears
Journal:  Hum Reprod Update       Date:  2012-05-30       Impact factor: 15.610

Review 7.  Cisplatin : an old drug with a newfound efficacy -- from mechanisms of action to cytotoxicity.

Authors:  Antonio Macciò; Clelia Madeddu
Journal:  Expert Opin Pharmacother       Date:  2013-07-22       Impact factor: 3.889

8.  Protocatechuic acid induces angiogenesis through PI3K-Akt-eNOS-VEGF signalling pathway.

Authors:  Zechun Kang; Haibo Zhu; Wanglin Jiang; Shuping Zhang
Journal:  Basic Clin Pharmacol Toxicol       Date:  2013-07-06       Impact factor: 4.080

9.  Zingerone ameliorates cisplatin-induced ovarian and uterine toxicity via suppression of sex hormone imbalances, oxidative stress, inflammation and apoptosis in female wistar rats.

Authors:  Erdal Kaygusuzoglu; Cuneyt Caglayan; Fatih Mehmet Kandemir; Serkan Yıldırım; Sefa Kucukler; Mehmet Akif Kılınc; Yavuz Selim Saglam
Journal:  Biomed Pharmacother       Date:  2018-03-26       Impact factor: 6.529

10.  Alleviation of endoplasmic reticulum stress protects against cisplatin-induced ovarian damage.

Authors:  Yuping Wu; Congshun Ma; Huihui Zhao; Yuxia Zhou; Zhenguo Chen; Liping Wang
Journal:  Reprod Biol Endocrinol       Date:  2018-09-03       Impact factor: 5.211

View more
  3 in total

Review 1.  The role of oxidative stress in ovarian aging: a review.

Authors:  Fei Yan; Qi Zhao; Ying Li; Zhibo Zheng; Xinliang Kong; Chang Shu; Yanfeng Liu; Yun Shi
Journal:  J Ovarian Res       Date:  2022-09-01       Impact factor: 5.506

2.  Amburana cearensis leaf extract protects against cisplatin-induced ovarian damage through regulation of p-PTEN and p-Akt proteins in mice.

Authors:  Bruna B Gouveia; Ricássio S Barberino; Vanúzia G Menezes; Alane P O Monte; Regina Lucia S Silva; Raimundo C Palheta; Larissa A Rolim; Emanuella C V Pereira; Raimundo G Oliveira; Jackson Roberto G S Almeida; Maria Helena T Matos
Journal:  Iran J Basic Med Sci       Date:  2022-06       Impact factor: 2.532

Review 3.  The Role of ROS as a Double-Edged Sword in (In)Fertility: The Impact of Cancer Treatment.

Authors:  Sara Mendes; Rosália Sá; Manuel Magalhães; Franklim Marques; Mário Sousa; Elisabete Silva
Journal:  Cancers (Basel)       Date:  2022-03-21       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.